AZ claims full control of Caelum’s AL amyloidosis drug in $500m dealAstraZeneca’s newly acquired Alexion will buy the remaining equity in rare disease specialist Caelum Biosciences in a deal Share XAZ claims full control of Caelum’s AL amyloidosis drug in $500m dealhttps://pharmaphorum.com/news/az-claims-full-control-of-caelums-al-amyloidosis-drug-in-500m-deal/
J&J’s Darzalex Faspro is first US therapy for rare blood disorderJohnson & Johnson’s Darzalex Faspro has become the first product approved by the FDA to treat light chain Share XJ&J’s Darzalex Faspro is first US therapy for rare blood disorderhttps://pharmaphorum.com/news/jjs-darzalex-faspro-is-first-us-therapy-for-rare-blood-disorder/
Chasing Janssen, Alexion and Caelum start phase 3 AL amyloidosis trialAlexion and development partner Caelum Biosciences have begun late-stage trials of their light-chain (AL) amyloidosis drug CAEL-101, snapping Share XChasing Janssen, Alexion and Caelum start phase 3 AL amyloidosis trialhttps://pharmaphorum.com/news/chasing-janssen-alexion-and-caelum-start-phase-3-al-amyloidosis-trial/
Janssen files Darzalex Faspro for rare disease light chain amyloidosisJanssen has filed a new formulation of its Darzalex in the US for the rare and potentially fatal Share XJanssen files Darzalex Faspro for rare disease light chain amyloidosishttps://pharmaphorum.com/news/janssen-files-new-darzalex-for-rare-disease-light-chain-amyloidosis/
